BOSTON, Sept. 11, 2024 ~ Boston Institute of Biotechnology, LLC (BIB) has recently made headlines in the biopharmaceutical industry as its CEO, Peng Jiao, has been awarded the prestigious 2024 Global Biologics CDMO Technology Leadership Award from Frost & Sullivan. This recognition celebrates BIB's groundbreaking contributions to biologics manufacturing, including the world's first 30,000L bioreactor and its Grand-CHO platform.

The demand for commercial-scale biologics has been on the rise, posing a challenge for the industry to meet global manufacturing capacity. Traditional methods relying on small-scale bioreactors have struggled to keep up with production needs efficiently. In response to this challenge, BIB has introduced transformative solutions that are revolutionizing the production of antibody drugs and biologics.

One of BIB's most notable achievements is the development of the world's largest stainless steel bioreactor with a working volume of 30,000L. This technology breaks current capacity barriers in biomanufacturing and allows for greater scalability while reducing production costs from hundreds of dollars per gram to just $10 per gram.

More on Boston Chron

• Boston: May 16 Traffic Advisory
• Boston: Mayor Wu Announces Expansion of Free Swim Lessons for Youth; Recognizes International Water Safety Day on May 15
• Fzata to Attend BIO International Convention 2025
• Boston: Traffic Advisory for May 14 - 24, 2025
• $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)

BIB has also developed a suite of innovative technologies to support large-scale biologics manufacturing while prioritizing cost efficiency. The integration of their 30,000L bioreactor with their proprietary Grand-CHO platform has set new industry standards. This "Three-in-One" approach combines advances in cell line development, process optimization, and ultra-large-scale production technology.

The Grand-CHO platform focuses on improving cell line stability, optimizing production processes, and maximizing yields. Its second-generation Epic-CHO cell line achieves high expression levels of 10 g/L at the mini-pool stage, doubling the stability of international competitors and paving the way for large-scale commercial production. Additionally, Grand-CHO technology reduces production cycle times by 30%, doubles yield per fermentation volume, and cuts restart time for 30,000L projects from 60 to 30 days.

BIB has also pioneered Pulse Continuous Manufacturing (PCM), an innovative production model that streamlines biologics production by releasing large volumes in a single upstream batch while processing multiple downstream batches continuously. This technology significantly improves line efficiency, enhancing production output by up to 300% compared to traditional methods. Combined with BIB's PanFlex®-Engineering and Grand-CHO platform, PCM is driving major advancements in biomanufacturing efficiency and cost-effectiveness.

More on Boston Chron

• Boston: Planning Department Advances Two New Office-To-Residential Conversion Projects
• LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
• Marc Soucy's Newest Music Series Approaches Its One Year Mark
• Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities
• Award-winning NJ Author Celebrates New Release and Multi-Author Collaboration

With its Boston-based R&D center and global production capabilities, BIB is committed to delivering state-of-the-art solutions that adhere to international standards. The company's focus on developing cutting-edge technologies and operational models has made it a leader in the CDMO space, providing high-quality, large-scale manufacturing services to biopharmaceutical companies worldwide.

Peng Jiao, founder, president & CEO of BiBo Pharma & Boston Institute of Biotechnology, LLC expressed his gratitude for the recognition from Frost & Sullivan and stated that BIB will continue to push the boundaries of biologics manufacturing to meet the increasing global demand while prioritizing cost efficiency. With their pioneering solutions and commitment to excellence, BIB is set to make a significant impact in the biopharmaceutical industry for years to come.

---

Show All News | Report Violation